CL2017001371A1 - Composiciones anticancerosas - Google Patents

Composiciones anticancerosas

Info

Publication number
CL2017001371A1
CL2017001371A1 CL2017001371A CL2017001371A CL2017001371A1 CL 2017001371 A1 CL2017001371 A1 CL 2017001371A1 CL 2017001371 A CL2017001371 A CL 2017001371A CL 2017001371 A CL2017001371 A CL 2017001371A CL 2017001371 A1 CL2017001371 A1 CL 2017001371A1
Authority
CL
Chile
Prior art keywords
prostate cancer
copylimer
arn
acrylate
met
Prior art date
Application number
CL2017001371A
Other languages
English (en)
Spanish (es)
Inventor
Dennis Martin Hester
Jason Michael Vaughn
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of CL2017001371A1 publication Critical patent/CL2017001371A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2017001371A 2014-12-05 2017-05-29 Composiciones anticancerosas CL2017001371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196594 2014-12-05

Publications (1)

Publication Number Publication Date
CL2017001371A1 true CL2017001371A1 (es) 2018-01-05

Family

ID=52006906

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001371A CL2017001371A1 (es) 2014-12-05 2017-05-29 Composiciones anticancerosas

Country Status (29)

Country Link
US (3) US20170360754A1 (cg-RX-API-DMAC7.html)
EP (2) EP4494636A3 (cg-RX-API-DMAC7.html)
JP (2) JP6937692B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200141533A (cg-RX-API-DMAC7.html)
CN (2) CN114886852A (cg-RX-API-DMAC7.html)
AR (1) AR102926A1 (cg-RX-API-DMAC7.html)
AU (3) AU2015358490B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017011788A2 (cg-RX-API-DMAC7.html)
CA (1) CA2969656A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017001371A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017005572A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170216A (cg-RX-API-DMAC7.html)
EA (1) EA201791222A1 (cg-RX-API-DMAC7.html)
ES (1) ES2996833T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241719T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069689T2 (cg-RX-API-DMAC7.html)
IL (2) IL252323B (cg-RX-API-DMAC7.html)
MA (1) MA41107B1 (cg-RX-API-DMAC7.html)
MD (1) MD3226841T2 (cg-RX-API-DMAC7.html)
MX (2) MX387933B (cg-RX-API-DMAC7.html)
NZ (1) NZ770528A (cg-RX-API-DMAC7.html)
PH (1) PH12017500964A1 (cg-RX-API-DMAC7.html)
PL (1) PL3226841T3 (cg-RX-API-DMAC7.html)
RS (1) RS66323B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201704267VA (cg-RX-API-DMAC7.html)
SM (1) SMT202400518T1 (cg-RX-API-DMAC7.html)
TW (2) TWI702966B (cg-RX-API-DMAC7.html)
UA (1) UA120950C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016090098A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3305285T (lt) 2012-09-26 2020-12-10 Aragon Pharmaceuticals, Inc. Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
PL3226843T3 (pl) 2014-12-05 2021-12-13 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
CN114886852A (zh) 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144646A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Apalutamide dispersed in applesauce for treating prostate cancer
CA3143199A1 (en) 2019-01-30 2020-08-06 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
US20220160695A1 (en) 2019-01-30 2022-05-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
EP4054572A1 (en) 2019-11-04 2022-09-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023122842A1 (es) * 2021-12-31 2023-07-06 Gador Limitada Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
CN116183787A (zh) * 2022-12-26 2023-05-30 郑州德迈药业有限公司 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法
CN121038790A (zh) 2023-03-16 2025-11-28 拜耳消费者护理股份有限公司 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020097A1 (en) 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
CA2400845A1 (en) 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same
DE60206889T2 (de) 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
BR0208421A (pt) 2001-04-02 2004-03-30 Astrazeneca Ab Formulação farmacêutica para administração a um paciente através das mucosas, dose farmacêutica diária, dispersão sólida, uso de pvp em dispersão sólida com 4'-ciano-alfa', alfa', alfa'-trifluoro-3-(4-fluoro fenilsulfonil)-2-hidróxi-2-metilpropiono-m-toluidet o, e, métodos para aumentar a estabilidade em armazenagem, a biodisponibilidade da droga e para reduzir a variação de concentrações de plasma do 4'-ciano-alfa', alfa', alfa',-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2 -metilpropiono-m-toluideto entre pacientes
SK15732003A3 (sk) * 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
WO2003063821A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
WO2003077827A1 (en) 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
CA2549572A1 (en) 2003-12-15 2005-06-23 Council Of Scientific & Industrial Research Taste masked pharmaceutical compositions comprising bitter drug and ph sensitive polymer
GB0502790D0 (en) 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
KR101332924B1 (ko) 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
SI3412290T1 (sl) 2006-03-27 2021-09-30 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
DK2414356T3 (en) 2009-04-03 2015-12-14 Hoffmann La Roche PROPAN-1-sulfonic acid {3- [5- (4-CHLORO-PHENYL) -1H-pyrrolo [2,3-b] pyridine-3- carbonyl] -2,4-difluorophenyl) -AMIDSAMMENSÆTNINGER AND USES THEREOF
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
CN102525876B (zh) 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
EP3333153A1 (en) 2011-06-15 2018-06-13 The U.S.A. as represented by the Secretary, Department of Health and Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en) 2012-03-21 2015-02-05 Emphascience, Inc. Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
MY187500A (en) 2012-06-07 2021-09-24 Aragon Pharmaceuticals Inc Crystalline forms of an androgen receptor modulator
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
KR102138544B1 (ko) * 2012-08-24 2020-07-28 다우 글로벌 테크놀로지스 엘엘씨 신규한 하이드록시알킬 메틸 셀룰로즈 아세테이트 석시네이트
DK3725778T3 (da) 2012-09-11 2021-09-20 Medivation Prostate Therapeutics Llc Formuleringer af enzalutamid
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence
LT3305285T (lt) * 2012-09-26 2020-12-10 Aragon Pharmaceuticals, Inc. Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EA028009B1 (ru) 2013-01-22 2017-09-29 Ф.Хоффманн-Ля Рош Аг Фармацевтическая композиция с улучшенной биодоступностью
KR20180021932A (ko) 2013-03-15 2018-03-05 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
BR112016002970A2 (pt) * 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
AU2015215000B2 (en) * 2014-02-05 2017-10-19 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
CA2969661C (en) 2014-12-05 2023-04-25 Aragon Pharmaceuticals, Inc. Anticancer compositions
CN114886852A (zh) 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物
PL3226843T3 (pl) 2014-12-05 2021-12-13 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
MX2018014846A (es) 2016-06-03 2019-03-14 Aragon Pharmaceuticals Inc Composiciones antineoplasicas.
KR20210023987A (ko) 2018-06-20 2021-03-04 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. Arn-509의 결정형, 그 제조방법 및 그 용도
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide

Also Published As

Publication number Publication date
NZ770528A (en) 2024-03-22
WO2016090098A1 (en) 2016-06-09
ES2996833T3 (en) 2025-02-13
KR102348320B1 (ko) 2022-01-10
MX2021013965A (es) 2022-01-04
EP3226841C0 (en) 2024-10-09
CO2017005572A2 (es) 2017-09-20
IL252323A0 (en) 2017-07-31
CN106999431A (zh) 2017-08-01
TW201630592A (zh) 2016-09-01
JP2017536398A (ja) 2017-12-07
AU2015358490B2 (en) 2021-04-08
SMT202400518T1 (it) 2025-01-14
MX387933B (es) 2025-03-19
CN106999431B (zh) 2022-03-04
EA201791222A1 (ru) 2017-09-29
SG11201704267VA (en) 2017-06-29
NZ731963A (en) 2024-03-22
EP3226841B1 (en) 2024-10-09
CN114886852A (zh) 2022-08-12
MX2017007203A (es) 2017-08-28
EP4494636A2 (en) 2025-01-22
AU2015358490A1 (en) 2017-06-08
TWI754258B (zh) 2022-02-01
IL279833B (en) 2022-03-01
US20170360754A1 (en) 2017-12-21
UA120950C2 (uk) 2020-03-10
AU2021201979A1 (en) 2021-04-29
IL252323B (en) 2021-04-29
JP2020143069A (ja) 2020-09-10
HRP20241719T1 (hr) 2025-02-14
MD3226841T2 (ro) 2025-06-30
AU2021201979B2 (en) 2023-02-02
EP4494636A3 (en) 2025-04-30
US12303493B2 (en) 2025-05-20
AU2023202710A1 (en) 2023-05-18
KR20170086656A (ko) 2017-07-26
RS66323B1 (sr) 2025-01-31
MA41107A (fr) 2017-10-10
KR20200141533A (ko) 2020-12-18
JP7174006B2 (ja) 2022-11-17
IL279833A (en) 2021-01-31
TW202031248A (zh) 2020-09-01
US20230233529A1 (en) 2023-07-27
BR112017011788A2 (pt) 2017-12-26
EP3226841A1 (en) 2017-10-11
AR102926A1 (es) 2017-04-05
JP6937692B2 (ja) 2021-09-22
CR20170216A (es) 2017-08-30
TWI702966B (zh) 2020-09-01
HUE069689T2 (hu) 2025-04-28
PL3226841T3 (pl) 2025-03-03
CA2969656A1 (en) 2016-06-09
PH12017500964A1 (en) 2017-10-18
MA41107B1 (fr) 2025-01-31
US20240293374A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
CL2017001371A1 (es) Composiciones anticancerosas
CL2017001373A1 (es) Composiciones anticancerosas
CL2017001372A1 (es) Composiciones anticancerosas
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
CL2017001916A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso (divisional solicitud 468-2016)
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
BR112016020953A2 (pt) composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção
MX357496B (es) Moduladores del receptor de estrógenos fluorados y sus usos.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2016001743A1 (es) Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio.
MX2018010546A (es) Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
EA201900562A1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
BR112016025866A2 (pt) composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão
CL2015001459A1 (es) Nueva composición farmacéutica.
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso